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Abstract
Esophageal adenocarcinoma (EAC) is rapidly increasing in incidence in Western cultures. 
Barrett’s esophagus (BE) is the presumed precursor lesion for this cancer. Several other risk 
factors for this cancer have been described, including chronic heartburn, tobacco use, Caucasian 
race, and obesity. Despite these known associations, most patients with EAC present with 
symptoms of dysphagia from late-stage tumors—only a small minority of patients are identified in 
screening and surveillance programs. Diagnostic analysis of EAC usually commences with upper 
endoscopy, followed by cross-sectional imaging. Endoscopic ultrasound is useful to assess local 
extent of disease as well as the involvement regional lymph nodes. T1a EAC may be treated 
endoscopically; some patients with T1b disease might also benefit from endoscopic therapy. 
Locally advanced disease is generally managed with esophagectomy, often accompanied by 
neoadjuvant chemoradiotherapy or chemotherapy. The prognosis is based on tumor stage: patients 
with T1a tumors have an excellent prognoses, whereas few patients with advanced disease have 
longterm survival.
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Esophageal adenocarcinoma (EAC) is among the most lethal conditions gastroenterologists 
face. Only 16% of patients survive 5 y and median survival time is less than 1 y; relatively 
little progress has been made in stemming the toll of this condition.1 EAC usually presents 
at a late stage, with most patients presenting with T3 or T4 disease. This is in part 
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responsible for its high mortality, as few therapies are available to cure patients with 
advanced-stage disease.
The incidence of EAC has increased greatly in the last 40 y, by approximately 600% from 
the 1970s. The reasons for this increase are incompletely understood. Many investigators 
have suggested that the concurrent epidemic of obesity may explain at least part of this 
increase. Treatment of EAC has also evolved—especially for early stage disease. Although 
in the past, gastroenterologists only performed the endoscopy and biopsy to diagnose the 
cancer, they are now integral members of the care team and are involved with many of the 
patients who are cured. For this reason, it is important for gastroenterologists to understand 
the risk factors and presentation of EAC, all the options for its treatment, and the expected 
outcomes based on the treatment provided.
We review the epidemiology, risk factors, staging, and treatment of EAC, focusing on early-
stage disease and endoscopic therapy, and prognoses of patients who receive different 
therapies. We conclude with likely future developments in care of these patients.
Epidemiology
Adenocarcinoma was once an exceedingly rare histological type of esophageal cancer. 
Beginning as early as the 1960s, the incidence of EAC began to increase in the United States 
(US).2 By the 1990s, adenocarcinoma was the predominant type of esophageal cancer in the 
US, surpassing squamous cell carcinoma.3, 4 In 2014, there were approximately 18,170 
incident esophageal cancers in the US, 59.9% of which were adenocarcinomas.5, 6 However, 
worldwide, squamous cell cancer is still the predominant form of esophageal neoplasia. In 
fact, there were approximately 52,000 incident cases of EAC worldwide in 2012, compared 
with an estimated 398,000 esophageal squamous cell carcinomas.7
EAC is most common in industrialized countries with populations of predominant European 
race; nearly 50% of all cases occur in Northwest Europe and North America (Figure 1).7 
Incidences are highest in the United Kingdom (UK), Ireland, France, and the Netherlands, 
indicating a Northern European predilection.8 EAC is rare in Asia and Africa, but China has 
approximately 18% of all incident cases worldwide, due to its large population.7 The 
incidence of EAC has continued to increase in the West, but may be reaching a plateau 
(Figure 2)8–10—the incidence of EAC in the US was 2.5/100,000 individuals/y in 2011.1, 9
There are several risk factors for EAC (Figure 3). Perhaps the most familiar is 
gastroesophageal reflux disease (GERD). In 1995, Chow et al associated adenocarcinoma of 
either the esophagus or gastric cardia with prior documentation of GERD (adjusted odds 
ratio [OR] = 2.1; 95% confidence interval [CI], 1.2–3.6).11 In 1999, Lagergren et al 
published a landmark population-based case–control study demonstrating that the risk of 
GERD was approximately 8-fold greater in patients with recurrent GERD symptoms 
compared to those without GERD symptoms.12 It is believed that in predisposed individuals, 
GERD can lead to erosive esophagitis, and after an aberrant healing process a metaplastic, 
specialized intestinal epithelium (Barrett’s esophagus).13 Barrett’s esophagus progresses to 
EAC in a small percentage of individuals, at a rate of approximately 0.12%/y to 0.60%/
y.14–16 A meta-analysis of population-based studies estimated that weekly GERD symptoms 
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increase the risk of EAC by about 5-fold.17 Patients with long-standing symptoms, nocturnal 
symptoms or more frequent symptoms are at higher risk. However, the severity of the 
symptoms is not associated with an increased risk of EAC.18
Although GERD is undoubtedly an important risk for EAC, most individuals with GERD 
never develop EAC.19 A systematic review of population-based studies found that a slight 
majority of patients with EAC deny any substantial prior symptoms of GERD.20 It is 
possible that chronic reflux of gastric contents could promote EAC without causing 
substantial symptoms before patients present with cancer.
Tobacco use is a strong risk factor for esophageal squamous cell carcinoma, but it is also a 
risk for EAC. Analyses of data from a consortium of researchers found that tobacco use 
increased the risk for EAC 2.18-fold (95% CI, 1.84–2.58).21 Alcohol use is also a strong risk 
factor for esophageal squamous cell carcinoma, but has not proven to be a consistent risk 
factor for EAC. In fact, there appears to be a moderate inverse association between alcohol 
use and risk of EAC.22 It is not clear whether alcohol use actually protects against EAC; it 
could be that individuals who develop EAC avoid alcohol use because it worsens the 
symptoms of GERD.
Obesity is a clear risk factor for EAC. A body mass index (BMI) of 30–34.9 kg/m2 is 
associated with a 2.39-fold increase in risk EAC, compared to a BMI of less than 25 kg/m2, 
with stronger effects for those with even greater BMIs.23 Abdominal obesity, in particular, is 
associated with Barrett’s esophagus, and is also associated with EAC (summary OR 2.51; 
95% CI 1.54–4.06).24
How might abdominal obesity contribute to development of EAC? Obesity has the 
mechanical effect of promoting formation of hiatal hernia, which is associated with an 
increased risk of GERD.25, 26 But abdominal obesity is associated with Barrett’s esophagus 
even after adjusting for GERD, and obesity is associated with EAC even in individuals 
without symptoms of GERD.23 In addition to its mechanical effect, abdominal obesity is 
associated with alterations in circulating levels of peptides that are associated with Barrett’s 
esophagus, and may also promote EAC.27 Abdominal obesity is associated with insulin 
resistance and hyperinsulinemia, which have been associated with multiple epithelial 
cancers. The metabolic syndrome has been associated with Barrett’s esophagus and 
EAC.28, 29 However, the evidence for an association between hyperinsulinemia or diabetes 
mellitus with Barrett’s esophagus or EAC has been inconsistent.27, 30–35
The insulin-like growth factor (IGF) pathway has been more strongly implicated in the 
development of EAC than insulin itself. Circulating levels of IGF binding protein-3 are 
inversely associated with the presence of Barrett’s esophagus.31 A polymorphism in the 
gene encoding IGF1 is associated with Barrett’s esophagus,36 and a polymorphism in the 
gene encoding the IGF1 receptor modifies the effect of obesity on the risk for Barrett’s 
esophagus and EAC.37 A polymorphism in the gene encoding IGF2 is also associated with 
EAC, perhaps more so among smokers.38 The IGF pathway might also be involved in the 
risk of progression from Barrett’s esophagus to EAC.39
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Studies have also found associations between blood levels of leptin and Barrett’s esophagus, 
and progression of Barrett’s esophagus to EAC.27, 30, 34, 40, 41 Barrett’s esophagus, and 
progression to EAC, has been associated with decreased levels of adiponectin (particularly 
the low molecular weight form) in some, but not all studies.27, 34, 40, 42, 43 These metabolic 
effects of obesity could have synergistic effects with GERD on the risk for Barrett’s 
esophagus and EAC.30, 44 Although obesity has been the primary focus for studies 
examining the effect of body habitus on risk of EAC, a recent analysis of data from a 
consortium of researchers found that short individuals are at greater risk for EAC than taller 
ones.45 The reason for that association is unclear.
Given the association of obesity with EAC, one might expect that physical activity and 
dietary habits would also be associated with EAC. Physical activity (either occupational or 
recreational) is weakly inversely associated with EAC (summary OR of greatest vs lowest 
category, 0.79; 95% CI, 0.66–0.94), with the strongest effects in people who exercise 
moderately or vigorously 5 days/week.46 The effect may persist including after adjusting for 
obesity. Some forms of activity, such as working in a stooped position and weight lifting, 
have been positively associated with GERD, but their specific effects on the risk of EAC 
have not been adequately studied.47
The association of dietary habits with the risk of EAC has been examined in many 
observational studies. Consumption of processed meats is associated with an approximate 
23%–37% increase in risk of EAC, when the highest levels of intake are compared with the 
lowest.48, 49 Dietary fiber intake is inversely associated with EAC (summary OR for greatest 
vs lowest category of intake, 0.66; 95% CI, 0.44–0.98), but there is substantial heterogeneity 
in results from individual studies.50 Intake of the anti-oxidant vitamins A, C, and E are 
inversely associated with EAC.51 Caution is necessary before inferring that any of these 
dietary habits are causal in the development of EAC, because increased intake of one food 
type or micronutrient is inextricably linked with increased or decreased intake of other food 
types and micronutrients. Many observational studies have associated dietary habits with 
outcomes, but these findings were not supported by subsequent randomized trials of dietary 
supplementation.52–54
Infection with Helicobacter pylori appears to protect against EAC. Individuals with EAC are 
approximately half as likely to have H pylori infection as individuals without (OR, 0.56; 
95% CI 0.46–0.68).55 In particular, the cytotoxin-associated gene A strain of H pylori 
appears to reduce risk of EAC. Infection of predominantly the gastric body, or the body and 
the antrum, reduces gastric acid production, which reduces acidic GERD and risk for 
EAC.56 However, infection predominantly in the antrum may be associated with increases in 
gastrin, with subsequent increase in gastric acid production.57 In Western countries, most H 
pylori infections occur predominantly in the antrum,58 so it is not clear whether its inverse 
association with EAC is due to a reduced incidence of GERD. H pylori infection is inversely 
associated with GERD in Asian countries, but does not appear to be so in Western 
countries.59
Another potential mechanism by which H pylori infection reduces risk for EAC could be 
that refluxed H pylori DNA reduces the inflammatory response to GERD.60, 61 Additionally, 
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individuals who are genetically predisposed to maintaining persistent infection with H pylori 
might also be predisposed to an inflammatory response to GERD.62–64 Lack of infection 
with H pylori might simply be a marker for other alterations in the microbiome of the 
esophagus and/or stomach that are directly related to the development of EAC.63 Further 
research is needed to understand the mechanisms of association between H pylori and EAC.
The strongest risk factors for EAC are advancing age and male sex. Men have 
approximately 6-fold the risk of EAC of women.9 Among men, circulating levels of free 
testosterone and free dihydrotestosterone are strongly associated with Barrett’s esophagus 
(adjusted ORs for 4th vs 1st quartile, 5.36; 95% CI, 2.21–13.0 and OR, 4.25; 95% CI, 1.87–
9.66, respectively).65 Among women who have had children, breast feeding is inversely 
associated with the risk of EAC, suggesting hormone effects.66 But no association among 
women has been found for the number of children, age of menarche or menopause, or use of 
hormone replacement therapy or oral contraceptives.66
The risk of EAC might be greater in men because of differences between sexes in use of 
tobacco or types of obesity. The estimated relative effects of tobacco use on EAC risk (ever 
use, or categorized by pack-y of use) are similar between men and women,21 but men more 
frequently use tobacco. Similarly, the effect of BMI on risk of EAC is similar between men 
and women,23 as is the effect of waist circumference on Barrett’s esophagus.67 However, 
the prevalence of abdominal obesity is greater among men, which could account for some of 
the increased risk for EAC among men. It is likely that the etiology of the difference in 
sexes is multifactorial, with differential distribution of some risk factors increasing the risk 
of EAC in men.
The regional differences observed in the incidence of EAC indicate that race is a strong risk 
factor for EAC. In the UK, the incidence of EAC is much lower among Asians and Africans 
than whites.68 Within the US, individuals of Asian descent and African-Americans have 
greatly decreased risk for EAC compared to non-Hispanic whites, with white Hispanics 
having an intermediate risk.69 The reasons for the differences across races are not clear. The 
effect of race might be mediated in part by differences in the prevalence of H pylori 
infection.70 In addition, although GERD symptoms are equally prevalent among the 
different races, whites are more likely to have erosive esophagitis, a lesion that is believed to 
be a necessary step in the development of EAC.71
Three genome-wide association studies have associated loci with Barrett’s esophagus; these 
are near or within CRTC1, BARX1, FOXF1, FOXP1, GDF7, and TBX5.72–74 CRTC1 
encodes a transcription coactivator that regulates the invasiveness and migration of 
esophageal cancer cells; it is also associated with age at menarche and with obesity.72, 73 
BARX1 encodes a homeobox transcription factor involved in esophageal differentiation.72, 73 
TBX5, FOXF1, and FOXP1 encode transcription factors that regulate esophageal 
development.73, 74 GDF7 encodes a protein in the bone morphometric protein pathway.73 
Differences in these or other alleles among races might account for the increased risk for 
EAC among Northern Europeans and their descendants.
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The use of certain medications has been associated with an increased or decreased risk of 
EAC. Observational studies of patients with Barrett’s esophagus demonstrate that that use of 
proton pump inhibitors reduced the risk of neoplastic progression by 71%, but results from 
different studies are heterogeneous.75 Conversely, medications that relax the lower 
esophageal sphincter and could thereby predispose people to GERD have been studied as 
potential risk factors for EAC.76–79 There appears to be no association between EAC and 
use of calcium channel blockers. Use of asthma medications such as theophylline or β-
agonists have been associated with Barrett’s esophagus and EAC, but these findings could 
be confounded by the indication for the medications, since asthma is associated with GERD. 
Use of aspirin and non-steroidal antiinflammatory drugs is associated with a decreased risk 
of EAC, particularly when used daily and for long duration.80 Finally, use of 
hydroxymethylglutaryl-CoA reductase inhibitors (statins) are associated with a decreased 
risk of EAC.81
Clinical Presentation and Diagnosis
Typically, patients with EAC present with dysphagia that progresses rapidly over months. 
Symptoms begin with subtle difficulty with solids, and progress to dysphagia for liquids as 
well. Oropharyngeal dysphagia is rare. The point of difficulty may be localized by the 
patient as cephalad as the sternal notch, even when the mass is in the distal esophagus. 
Weight loss and fatigue are common. In rare instances, patients present with iron-deficiency 
anemia. Although patients with GERD frequently undergo upper endoscopy and 
surveillance for Barrett’s esophagus, fewer than 15% of EAC cases are detected during 
surveillance endoscopies.82–84 Most patients with EAC present with symptoms and 
advanced disease. Only approximately 25% of patients with EAC have localized disease at 
the time of presentation,9 severely limiting effective treatment options.
Cross-sectional imaging analysis, such as with computed tomography (CT), does not 
accurately identify localized EAC. Barium esophagrams can identify irregular strictures or 
masses, but upper endoscopy with biopsy collection and histologic analysis is the standard 
for diagnosis. During endoscopy, EAC can appear as a stricture, mass, raised nodule, 
ulceration, or a subtle irregularity in the mucosa, including a depression. EAC has been 
detected in biopsy specimens from regions of Barrett’s esophagus that appear flat during 
endoscopy. During endoscopy, care should be taken to document the proximal and distal 
extents of the tumor, and their relation to the gastroesophageal junction, because these have 
implications for surgical management. For example, if the tumor involves the stomach more 
distally than the cardia, a gastric pull-up procedure may not be feasible, and colonic 
interposition might be required. For tumors that involve the entire circumference of the 
lumen, the normal anatomy of the gastroesophageal junction can be obliterated, making the 
documentation of its location inaccurate. Occasionally, smaller tumors are encountered that 
may be amenable to endoscopic therapy. As such, the size, location, and morphology of the 
tumor, as visualized by endoscopy, should be documented to aid in the planning of such 
therapy.
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EAC is staged based on the American Joint Committee on Cancer system, last updated in 
2010 (Table 1).85 This was the first time staging of EAC was separated from that of 
squamous cell carcinoma. The esophageal wall has layers of mucosa, submucosa, 
muscularis propria, and adventitia (Figure 4). The mucosal layer includes the epithelium, 
lamina propria, and muscularis mucosae, and is separated from the submucosa by a 
basement membrane. High-grade dysplasia is synonymous with carcinoma in situ (Stage 0), 
and is confined to the epithelium. If cells with the same appearance have invaded the lamina 
propria, the lesion is classified as invasive cancer.
T1a cancers are confined within the mucosa and are often called intramucosal cancers; they 
can invade the lamina propria, as deeply as the muscularis mucosae. The intra-observer 
agreement among pathologists for distinguishing high-grade dysplasia from T1a cancer is 
poor.16, 17 Therefore, it should not be surprising that the patients high-grade dysplasia vs 
those with T1a cancers have similar times of survival (Supplemental Figure 1).86 In contrast, 
patients with tumors that invade even the submucosa (T1b) have considerably worse 
prognoses, similar to those of patients with T2 tumors (Supplemental Figure 1). T2 tumors 
invade the muscularis propria, T3 invade the adventitia, and T4 tumors invade adjacent 
structures (Figure 4). In the 2010 American Joint Committee on Cancer staging system, 
regional lymph node involvement included periesophageal cervical nodes to the celiac 
nodes. In the earlier 2002 system, celiac nodes were considered distant metastases. The 2010 
system categorizes the number of lymph nodes involved into 0 (N0), 1 or 2 (N1), 3 to 6 
(N2), and 7 or more (N3).
A number of modalities are available to stage esophageal cancer. For staging the tumor 
depth, endoscopic resection distinguishes T1a from those that invade more deeply.87 Cross-
sectional imaging techniques such as CT or positron emission tomography (PET) has no 
practical role in staging depth of early-stage EACs. Although endoscopic ultrasound (EUS) 
is more accurate than CT or PET at staging tumor depth, none of these accurately stage 
shallow tumors.88, 89 Furthermore, these techniques can over-stage superficial EAC, which 
is actually amenable to endoscopic therapy. Therefore, for cases in which EUS analysis 
indicates T1b disease, endoscopic mucosal resection should still be considered. EUS may be 
particularly inaccurate if strictures prevent passage of the echoendoscope to the full extent of 
the tumor. A meta-analysis of studies of regional lymph node staging found EUS to detect 
T1b disease with the highest level of sensitivity (80%), but slightly less specificity (70%), 
than PET (57%sensitivity and 85% specificity).90
EUS only rarely identifies distant metastases such as those to the liver or peritoneum. CT 
with intravenous contrast is the main modality used to identify distant metastases. PET can 
identify incrementally more metastases than CT alone.90 Increasingly, PET is performed 
with a hybrid scanner that performs a non-contrast CT in the same setting, to aid in 
localizing any uptake identified by PET. In practice, once a diagnosis of EAC is made, 
based on analysis of mucosal biopsies, patients typically undergo PET/CT, or CT with 
intravenous contrast, to identify distant metastases. PET/CT is the most accurate form of 
imaging for this purpose, with greater accuracy than either PET or CT alone. If no distant 
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metastases are found, then EUS can be used to stage regional lymph nodes, and to a lesser 
extent, tumor depth. In cases where the tumor appears to be subtle or small by endoscopy 
(typically in patients undergoing surveillance for Barrett’s esophagus), endoscopic resection 
of the lesion is often considered before additional imaging, to determine whether the tumor 
was invasive and exclude dysplasia confined to the epithelium.
For patients with T1a tumors, the likelihood of metastasis is lower than the false-positive 
rates of PET/CT or EUS, meaning that most positive results are false.91 Given the extremely 
low likelihood of lymph node involvement in patients with T1a cancer, the value of PET/CT 
or EUS is questionable.92–94 Additionally, in patients with more advanced disease, PET/CT 
is not a good modality for assessing for brain metastases, due to the avid glucose uptake of 
normal brain.95 Magnetic resonance imaging should be considered for patients with 
neurologic symptoms, to detect metastases to brain. Locally advanced lesions that extend to 
the middle third of the esophagus could also involve the posterior membranous trachea. 
Bronchoscopy should be considered to assess invasion and, in the event of fistula formation, 
stent the bronchus.96
Treatment
Initial treatment approaches for EAC depend on several factors, including the stage and 
grade of the tumor, the location of the tumor, the comorbidities and age of the patient, and 
institutional expertise in providing therapy. Given that systemic therapy for EAC is often not 
curative, it is imperative to correctly identify patients who may be eligible for curative 
endoscopic or surgical therapy. Multi-modal therapies are used for patients with late-stage 
disease, although the value of this approach has not been completely elucidated.
Superficially Invasive Adenocarcinoma (T1a and T1b Disease)
Perhaps no aspect of the treatment of EAC has evolved more in the past 10 y than 
endoscopic therapy for superficially invasive adenocarcinoma. Although surgical and 
endoscopic therapies are available for superficial disease, endoscopic therapies have moved 
to the forefront, due to their high level of efficacy and low morbidity. New endoscopic 
treatment modalities, and more widespread and aggressive use of endoscopic therapy, have 
changed outcomes in the small proportion of patients with early-stage EAC.
Endoscopic Therapy—Most endoscopic therapy for EAC begins with endoscopic 
resection.97 This is performed as a staging and a therapeutic measure, in that complete 
excision of a mucosal EAC improves a patient’s prognosis. The resection can be performed 
as an endoscopic mucosal resection, using either band ligation methods or cap-and-snare 
methods,98 or as an endoscopic submucosal dissection (ESD).99 The chief advantage of 
ESD is that it allows for complete en bloc resection and assessment of the lateral margins of 
the lesion.100, 101 However, ESD is technically more challenging, and relatively few US 
centers have the capability to perform it. The most important piece of prognostic 
information obtained from endoscopic resection is the depth of invasion; endoscopic 
mucosal resection and ESD each provide this information and allow for the tumor to be 
staged. More than 1 endoscopic session may be necessary to achieve complete resection.
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Several features define tumors that are amenable to endoscopic therapy.102–105 Moderate- or 
well-differentiated grade, lack of lymphovascular invasion, lesion size less than 3 cm, and 
confinement to the mucosa are all features of a good prognosis. Invasion into the submucosa 
is a marker of T1b disease, and is graded as superficial, moderate, or deep invasion (sm1, 
sm2, and sm3, respectively). Even superficial (sm1) invasion into the submucosa has been 
associated with a substantial rate of lymph node involvement, making endoscopic therapy 
inadequate for patients with any submucosal extension of disease.106–108 However, more 
recent data indicate that sm1 tumors can be effectively treated by endoscopy.102, 109 Given 
the inconsistencies in results, such patients require multi-disciplinary treatment teams that 
consider not only tumor characteristics, but also patient features.
Studies of endoscopic management of superficial EAC at tertiary care centers have reported 
rates of local control of neoplasia greater than 95%.97 Survival times of these patients may 
not differ from those of from age- and sex-matched cohorts without neoplasia. These 
excellent results were achieved by careful selection of patients for the treatment; those with 
tumor invasion of the submucosa did not receive this conservative therapy, but were instead 
sent for consultation for surgical therapy.102, 110
After complete endoscopic resection, endoscopic eradication therapy is recommended, to 
remove any residual Barrett’s esophagus. As many as 30% of patients who undergo 
endoscopic resection of EAC without adjuvant eradication therapy develop recurrent 
EAC.97, 111–113 A number of eradication therapies are available, although there is no level 1 
evidence for the superiority of one over another after endoscopic resection of superficial 
EAC.
The most-reported modality is radiofrequency ablation (RFA). Data from prospective cohort 
studies demonstrate that 80% or more of subjects with T1a EAC can achieve complete 
eradication of all dysplasia with RFA.114–116 However, in an analysis of a cohort that 
included patients without cancer at baseline, 33% had recurrence of intestinal metaplasia 
within 2 y after complete eradication of Barrett’s esophagus.117 Rates of recurrence in 
patients with T1a tumors may be higher than those of patients who undergo RFA for less-
advanced lesions, such as Barrett’s esophagus with no dysplasia (Supplemental Figure 2).118 
Additionally, these neoplasias might be of a higher grade in subjects treated endoscopically 
for EAC than those treated with RFA for BE. For these reasons, aggressive endoscopic 
surveillance is recommended in patients after they have undergone EMR and RFA for 
superficial EAC.119
Although evidence-based guidelines are not available, experts recommend surveillance 
every 3 months for the first year following endoscopic therapy, every 6 months in the 
second year, and annually thereafter.120 Endoscopic cryotherapy121 and photodynamic 
therapy122 have also demonstrated efficacy for patients with EAC, although there are fewer 
data on outcomes. Stepwise radical endoscopic resection of residual BE can be successfully 
undertaken after EMR of superficial EAC,123, 124 but appears to be associated with an 
unacceptably high rate of stricture formation, compared to ablative therapy.125 Figure 5 
presents a suggested algorithm to manage patients with early-stage EAC.
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Esophagectomy—Although surgery is less commonly used to treat superficial neoplasia, 
there are situations in which it is appropriate to consider esophagectomy. For instance, in 
subjects with poor esophageal transit secondary to stricturing and aperistalsis, preservation 
of the esophagus with endoscopic therapy can still have poor functional outcome. In these 
situations, esophagectomy can address the neoplasia as well as the poor esophageal function. 
In tertiary care centers, esophagectomy for high-grade dysplasia or T1a cancer is associated 
with less than 3% mortality. However, morbidity, primarily in the form of pulmonary and 
wound infection, and anastamostic leaks occur in more than 30% of patients undergoing 
esophagectomy.126, 127
Locally Advanced Adenocarcinoma
Although several high-quality studies have been performed, the optimal approach to locally 
advanced EAC is unclear. In the US, the most common approach involves neoadjuvant 
chemotherapy and external beam radiotherapy (CRT). There have been a range of results 
reported on the benefits of neoadjuvant chemotherapy or CRT before surgery, compared 
with only surgery. Some studies reported increases in survival and likelihood of pathological 
R0 resection after combined therapy,128–130 whereas others did not.131, 132 Study findings 
are difficult to interpret because patients with EAC and those with SCC, as well as patients 
with different stages of disease have been included in many studies.
Meta-analyses of the value of CRT before resection have found that CRT increases overall 
survival times and rates of R0 resection, compared to surgery alone, making CRT the most 
common approach in the US133–135 In most trials, patients were given cisplatin or 
carboplatin with 5-fluorouracil. Concurrent external beam radiation dosage varied from 35 
to 45 Gray. There are data to support the efficacy of an alternative approach, in which only 
chemotherapy is given before resection; this is commonly used in the UK136, 137 It is unclear 
how much neoadjuvant CRT improves outcomes of patients with early-invasive EAC (T1b); 
surgical resection without neoadjuvant therapy can be recommended in this subgroup of 
patients.
Most patients with locally advanced neoplasia have been treated with surgery, not only with 
curative intent, but also to relieve dysphagia and improve quality of life for patients who 
could not be cured. The advent of stenting has decreased the use of surgery for palliation.
Esophagectomy—Esophagectomy is an important component of therapy used to treat 
patients with locally advanced EAC. Several approaches have been described—each has its 
merits. Ivor-Lewis esophagectomy involves abdominal and right thoracic incisions. The 
stomach is mobilized through the abdominal incision, the esophagus removed, and lymph 
nodes collected through the chest incision; an intra-thoracic esophagogastric anastomosis is 
then made. This approach has the advantage of providing an excellent yield of lymph nodes 
for histologic assessment, and good exposure to the lesion, especially for cancers in the 
distal third of the esophagus.
Transhiatal esophagectomy involves left neck and abdominal incisions.138 The esophagus is 
mobilized by blunt dissection through the hiatus from the abdominal incision. An 
anastomosis is made via the neck incision. This approach generally avoids a thoracotomy, 
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but provides less exposure to the tumor site and potentially fewer lymph nodes for 
examination. Tri-incisional esophagectomy uses a laparotomy, a thoracotomy, and a neck 
incision, allowing excellent lymphadenectomy of abdominal and thoracic lymph nodes. 
Neck anastomosis is generally performed on the left side to decrease the likelihood of 
recurrent laryngeal nerve injury.
Minimally invasive esophagectomy is the most recently described approach, and relies on 
thoracoscopic access to the chest and laparoscopic access to the abdomen to achieve 
excision of the esophagus.139 It is associated with the quickest recuperation, and because of 
the expanded abilities of thoracoscopy, can, in expert hands, provide adequate lymph node 
yield to assess for metastatic disease.140, 141
Which of these approaches is best is hotly contested issue in the surgical literature.142–144 
Single-center studies from groups with expertise in each of the 3 approaches have provided 
excellent results.139, 145, 146 There is no level-1 evidence that any approach increases 
survival times, compared with the others. Randomized studies have associated trans-hiatal 
approaches with less morbidity than transthoracic approaches, but percentages of patients 
with long-term survival did not differ significantly.147 In general, local expertise is probably 
a better predictor of outcome than approach.
One recurrent theme in the surgical literature is that center volume of esophagectomy is an 
important deciding factor of outcome148–150. Thirty-day mortality is associated with volume 
of esophagectomies performed at the center. In addition to operator technique, aspects of 
care such as intensive care unit management and early detection of complications likely play 
a role in these differential outcomes. Despite the availability of neoadjuvant therapy for 
patients with locally advanced disease, mortality is high. The median survival times reported 
for patients who received CRT in these trials ranged from 16 to 49 months; 3 y rates of 
overall survival ranged from 32% to 59%.
These disappointing results led to the development of newer chemotherapeutic agents, 
designed to target cancer cells. Molecular profiling of individual cancers may allow the use 
of agents tailored to the susceptibility of the tumor. For example, gastric and gastro-
esophageal junction tumors, which overexpress human epidermal growth factor receptor 2, 
appear to respond to trastuzumab, when combined with cisplatin and a fluoropyrimidine.151 
Tumor characterization may also allow clinicians to discern the mechanisms by which the 
tumor protects itself from the effects of CRT. For instance, because standard CRT induces 
formation of DNA adducts, therapeutics might be developed to alter production of proteins 
that repair the adducts.152 Studies are underway to investigate both of these approaches. 
Ramucirumab, an antibody against vascular endothelial growth factor receptor-2, showed 
some efficacy as a salvage therapy for gastroesophageal junction and gastric cancers in 
early-stage trials.153 However, its effect was modest, increasing median survival time by 1.4 
months (hazard ratio, 0.77; 95% CI, 0.603−0.998).
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Patients with Unresectable or Metastatic Disease, and Patients who Cannot Undergo 
Surgery
Chemoradiation or chemotherapy is a definitive therapy for patients with advanced disease 
that cannot be cured by surgery. They are generally treated by chemotherapy or CRT, and 
their 5 y rate of survival is less than 15%. For these patients, multi-modal therapy with 
chemoradiation appears superior to radiation alone, increasing median survival by 
approximately 4 months.154, 155
Endoscopic therapy also has an important role in palliating locally advanced and distant 
metastatic disease. Dilation using balloons or bougies may provide transient relief of 
dysphagia, but is unlikely to have long-lasting effect, given the aggressive nature of the 
lesion. Palliative tumor debulking of more advanced lesions, via resection, thermal 
therapies, cryotherapy, and/or photodynamic therapy, have all been described, and can 
improve quality of life, and in some instances, forestall stent placement.121, 156–159 A 
program of intermittent palliative endoscopic treatments at 2–3 month intervals may attain 
local control of the disease, allowing adequate oral intake and decreased dysphagia.121
Placement of endoscopic stents has become increasingly less difficult with improved 
technology. Covered self-expandable metal stents are often used for this indication, and their 
use is associated with marked improvement in dysphagia symptoms.160, 161 However, this 
therapy has not been shown to increase survival times, and patients and clinicians must be 
familiar with the potential side effects of stent placement. One common side effect is stent 
migration, which occurs in up to 15% of patients and can require surgery for removal.160 
Chest pain is also common, and can be difficult to distinguish from pain secondary to the 
EAC.162, 163 The most catastrophic complication is erosion into a major blood vessel, which 
is often a terminal event.164, 165 Because of excellent initial rates of response of tumors to 
CRT, stenting at the time of tumor discovery is generally not recommended, given the 
additional risk it entails, the chance of migration after tumor debulking from CRT, and the 
impediment it presents for possible future endoscopic cytoreductive therapy.
Conclusion
EAC is an increasingly common and highly lethal tumor that is associated with Barrett’s 
esophagus—its precursor lesion. Barrett’s esophagus and EAC are most common in elderly, 
overweight Caucasian men with symptoms of GERD. Other risk factors include tobacco, 
lack of H pylori infection, and certain medications; there is an inverse association between 
EAC and use of NSAIDs. EAC most commonly presents with dysphagia, but patients may 
also present with weight loss, anemia, or manifestations of distant metastases. Only a small 
minority of these cancers in most series present as part of an endoscopic surveillance 
program for BE.
Diagnostic analysis generally begins with an upper endoscopy. The lesion is usually obvious 
during white-light endoscopy, and biopsies of the lesion confirm the presence of EAC. For 
tumors that are not bulky, EMR is required to differentiate between T1a and more deeply 
invasive EAC. PET/CTcan identify distant metastases. In those cases where the disease is 
confined to the mediastinum, EUS, potentially with sampling of any pathologic-appearing 
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lymph nodes, can help define depth of invasion and nodal status. In some cases, 
bronchoscopy and/or brain magnetic resonance imaging are necessary to rule out tumor 
involvement of the trachea or brain.
Multiple disease- and patient-specific characteristics must be considered in selecting the 
optimal treatment for patients with EAC. The most important of these is the stage of the 
tumor at diagnosis. T1a tumors can be effectively treated with endoscopic therapy, most 
commonly by endoscopic resection followed by ablative therapy. Invasion into the 
submucosa, especially the deep submucosa, is associated with an increased rate of lymph 
node involvement, making endoscopic therapy a suboptimal approach in the good surgical 
candidate. For patients with stage T1b tumors, esophagectomy may be employed as a sole 
therapeutic modality. For patients with locally advanced disease without distant metastases, 
the most common treatment in the US is neoadjuvant CRT, followed by esophagectomy in 
patients who are candidates for surgery. For those with distant metastatic disease, definitive 
CRT is often used. In patients with local advanced disease, as well as those with distant 
metastases, endoscopic therapy can offer significant palliation of dysphagia. Because of the 
vital role of endoscopic therapy in the diagnosis and treatment of patients with EAC, 
endoscopists must be included in the cancer care team and should be engaged in multi-
modal planning conferences.
Despite remarkable advances in the care of EAC patients, overall mortality remains high, 
with 5 y rates of survival less than 20%. This is because most patients present with late-stage 
disease, and are not eligible for the highly effective, usually curative, endoscopic therapies 
that have evolved over the last 15 y. Although advances in radiotherapy and surgical 
technique have reduced the toxicity of these therapies, the likelihood of R0 resection, based 
on pathology analysis, and long-term survival after these non-endoscopic therapies is 
unacceptably low. This points to a need for improved screening for this condition, to detect 
disease at earlier, more curable stages, as well as improved prevention with endoscopic, 
behavioral, and medical approaches. Also, molecular characterization of these tumors may 
allow for less toxic, more tumor-specific, therapies.
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Figure 1. Global Differences in Incidence of Histological Subtypes of Esophageal Cancer
Age-standardized incidence rate (ASR) per 100,000 of (A) esophageal adenocarcinoma and 
(B) squamous cell carcinoma in men. AC, adenocarcinoma; SCC, squamous cell carcinoma. 
(Reproduced with permission from: Arnold M, Soerjomataram I, Ferlay J, et al. Global 
incidence of oesophageal cancer by histological subtype in 2012. Gut published online 
10/15/2014 as doi:10.1136/gutjnl-2014-308124).
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Figure 2. Trend in US Incidence of EAC
Graph shows Surveillance Epidemiology and End Results (SEER) cancer registry 9 
esophageal adenocarcinoma incidence and incidence-based mortality, 1975 to 2009. From 
1975 to 1997, EAC incidence increased at an annual percentage change (APC) of 8.4 (95% 
confidence interval [CI] = 7.7–9.1), whereas the APC was 1.6 (95% CI = 0.0–3.3) from 
1997 to 2009. For incidence-based mortality, the APC was 8.0 from 1978 to 1998 (95% CI = 
7.2–8.8) and 1.1 from 1998 to 2009 (95% CI = 0.7 to 2.9). All rates were age-adjusted to the 
2000 Standard population using 19 age groups. (Reproduced with permission from: Hur C, 
Miller M, Kong CY, et al. Trends in Esophageal Adenocarcinoma Incidence and Mortality. 
Cancer 2013;119:1149–58).
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Figure 3. Risk Factors for EAC
The primary risk factors for esophageal adenocarcinoma include male sex, advancing age, 
white race, GERD, obesity, and tobacco use. The effect of obesity is likely mediated both 
through a mechanical effect promoting GERD and a hormonal effect through alterations in 
circulating adipokines and other peptides, and appears to be a major risk factor for both BE 
and EAC. A deranged gastro-esophageal junction, noted above with a large hiatal hernia, 
allows free reflux of gastric contents. H pylori infection protects against EAC, and Barrett’s 
esophagus is its only known precursor.
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Figure 4. Tumor Depth Staging for EAC
There are 4 main layers of the esophageal wall: mucosa, submucosa, muscularis propria, and 
adventitia. The mucosa is further divided into the epithelium, lamina propria, and muscularis 
mucosae. Dysplasia is confined to the epithelium. Intramucosal tumors (T1a) invade the 
lamina propria or muscularis mucosae. Tumors that invade the submucosa are classified 
T1b. T2 tumors invade the muscularis propria, T3 tumors invade the adventitia, and T4 
tumors invade adjacent structures.
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Figure 5. Endoscopic Management of Early EAC
Depth of invasion, as assessed by EMR or ESD, is the key to appropriate subsequent 
therapy. EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; LVI, 
lymphovascular invasion.
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Table 1
Staging of Esophageal and Esophagogastric Junction Adenocarcinoma.
Primary Tumor (T)
Tis High-grade dysplasia
T1a Tumor invades lamina propria or muscularis mucosa (intramucosal)
T1b Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 Tumor invades adventitia
T4a Resectable tumor invading pleura, pericardium, or diaphragm
T4b Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc.
Regional Lymph Nodes (N)
NX Regional lymph node(s) cannot be assessed
N0 No regional lymph node metastases
N1 Metastasis in 1–2 regional lymph nodes
N2 Metastasis in 3–6 regional lymph nodes
N3 Metastasis in 7 or more regional lymph nodes
Distant Metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Histologic Grade (G)




G4 Undifferentiated – stage grouping as G3 squamous
Anatomic Stage / Prognostic Groups
Stage T N M G
0 Tis (HGD) N0 M0 1,X
IA T1 N0 M0 1–2,X
IB T1 N0 M0 3
T2 N0 M0 1–2,X
IIA T2 N0 M0 3
IIB T3 N0 M0 Any
T1-2 N1 M0 Any
IIIA T1-2 N2 M0 Any
T3 N1 M0 Any
T4a N0 M0 Any
IIIB T3 N2 M0 Any
IIIC T4a N1-2 M0 Any
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Anatomic Stage / Prognostic Groups
Stage T N M G
T4b Any M0 Any
Any N3 M0 Any
IV Any Any M1 Any
Note: Based on 2010 AJCC TNM
NX: Regional lymph node(s) cannot be assessed; GX: Grade cannot be assessed.
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